Fairvalue-Calculator Fairvalue-Calculator
EN DE

Guhan Pharmaceutical Group (000590) Fair Value & Analysis

Industrials · CN · Market cap 74.0B KRW

Price69,200 KRW
Fair Value352,428 KRW
Upside+409.3%
Quality80/100
Evidence: Low Range 275,238 KRW – 440,535 KRW

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Guhan Pharmaceutical Group (000590) currently trades at 69,200 KRW, while our model-based Fair Value estimate is 352,428 KRW — implying the stock looks roughly 409.3% undervalued today. We read business quality at 80/100 (high quality), in the Industrials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Guhan Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells traditional Chinese medicines, chemical drugs, and health food under the Guhan brand in China. It operates through the Pharmaceutical and Health Product Manufacturing and Sales Business, Active Pharmaceutical Ingredient (API) Manufacturing and Sales Business, and Other Business segments. The company offers prescription and over-the-counter drugs, such as tonics, cardiovascular drugs, children's nutritional supplements, cold and flu remedies, and heat-clearing and detoxifying drugs. It also engages in nutrition and health consulting services; Chinese herbal medicine cultivation; medical research and experimental development; cultural and artistic exchange planning; medical consultation; internet sales; technology promotion, consulting, and agency services; outpatient services; and pharmaceutical wholesale and retail activities. The company was formerly known as Tus-Pharmaceutical Group Co., L…

Open the full interactive analysis →

Similar stocks

Techtronic Industries Company (TTNDF) -18% Snap-on Incorporated (SNA) -10% RBC Bearings Incorporated (RBC) -68% Lincoln Electric Holdings (LECO) -45% Stanley Black & Decker, Inc (SWK) -36% AB SKF (publ) (SKUFF) -17%

Frequently asked questions

Is Guhan Pharmaceutical Group (000590) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 352,428 KRW versus a price of 69,200 KRW — about +409% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 000590?
Our 21-model fair value for Guhan Pharmaceutical Group is 352,428 KRW (as of Jun 25, 2026), built from audited fundamentals. The current price is 69,200 KRW.
What is the quality score of 000590?
Guhan Pharmaceutical Group has a Quality Score of 80/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.